2024
Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer.
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 101097upj0000000000000679. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosis
2023
Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer
Leapman M, Sutherland R, Gross C, Ma X, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman‐Green D. Patient experiences with tissue‐based genomic testing during active surveillance for prostate cancer. BJUI Compass 2023, 5: 142-149. PMID: 38179031, PMCID: PMC10764160, DOI: 10.1002/bco2.277.Peer-Reviewed Original ResearchActive surveillanceProstate cancerGene expression testGenomic testingCancer riskPatient experienceGrade group 2 prostate cancerGleason Grade Group 1Risk prostate cancerGrade group 1Prostate cancer riskProstate cancer managementProstate cancer aggressivenessHereditary cancer riskGermline genetic testsTissue-based testsGenomic test resultsConclusions PatientsInitial biopsyPhysician recommendationPatient knowledgePatient counsellingConventional content analysisCancer managementExpression testPD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER
Leapman M, Wang R, Long J, Sprenkle P, Ma X, Gross C. PD10-01 ASSOCIATIONS BETWEEN PROSTATE MRI AND GENOMIC TESTING AND TREATMENT INTENSIFICATION AMONG PATIENTS WITH LOCALIZED PROSTATE CANCER. Journal Of Urology 2023, 209: e326. DOI: 10.1097/ju.0000000000003250.01.Peer-Reviewed Original ResearchPatient experiences with tissue-based genomic testing during active surveillance for prostate cancer.
Leapman M, Sutherland R, Gross C, Ma X, Jeong F, Seibert T, Cooperberg M, Catalona W, Loeb S, Schulman-Green D. Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer. Journal Of Clinical Oncology 2023, 41: 333-333. DOI: 10.1200/jco.2023.41.6_suppl.333.Peer-Reviewed Original ResearchActive surveillanceProstate cancerGene expression testGenomic testingCancer riskPatient experienceGleason Grade Group 1Risk prostate cancerGrade group 1Routine clinical careProstate cancer riskGroup 2 tumorsProstate cancer managementProstate cancer aggressivenessHereditary cancer riskGermline genetic testsTissue-based testsRace/ethnicityInitial biopsyPatient knowledgeMean agePatient counselingCancer managementClinical careExpression test
2021
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptakeRegional Adoption of Commercial Gene Expression Testing for Prostate Cancer
Leapman MS, Wang R, Ma S, Gross CP, Ma X. Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. JAMA Oncology 2021, 7: 52-58. PMID: 33237277, PMCID: PMC7689565, DOI: 10.1001/jamaoncol.2020.6086.Peer-Reviewed Original ResearchConceptsProstate cancerCohort studyGenomic testingTissue-based genomic testsProportion of patientsDynamic cohort studyProstate cancer careProstate cancer screeningHospital referral region levelCommercial health insuranceGene expression testingEligible patientsMedian ageCancer careCancer screeningInclusion criteriaFindings highlight factorsHRR levelMAIN OUTCOMEAdministrative claimsGroup 2Group 1Medicare beneficiariesPatientsMedian household income
2020
MP23-17 ASSOCIATIONS OF REGIONAL-LEVEL ADOPTION OF PROSTATE MRI AND GENOMIC TESTING AND OBSERVATION FOR PROSTATE CANCER
Leapman* M, Wang R, Ma X, Gross C. MP23-17 ASSOCIATIONS OF REGIONAL-LEVEL ADOPTION OF PROSTATE MRI AND GENOMIC TESTING AND OBSERVATION FOR PROSTATE CANCER. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000856.017.Peer-Reviewed Original Research